Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is a biotechnology company focused on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer. This news page aggregates company announcements, clinical updates, regulatory developments, and financial disclosures related to Iovance’s TIL platform and commercial activities.
Readers can find news about Amtagvi, which Iovance describes as the first FDA-approved T cell therapy for a solid tumor indication, as well as updates on its use in advanced melanoma and other solid tumors. Coverage includes information on Health Canada’s conditional approval of Amtagvi for certain patients with unresectable or metastatic melanoma, and ongoing work to expand access through treatment centers and international markets.
The feed also features interim data from key clinical trials, such as registrational Phase 2 studies of lifileucel in advanced non-small cell lung cancer and other solid tumors, along with reports on next-generation programs like gene-edited TIL therapies and modified IL-2 analogs. Corporate news items include quarterly financial result announcements, conference presentations, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and capital markets transactions described in SEC filings.
Investors, analysts, and healthcare professionals can use this page to follow how Iovance communicates progress on its TIL pipeline, commercial execution for Amtagvi and Proleukin, and interactions with regulators. Regularly reviewing these updates provides context on the company’s development trajectory and its efforts to advance TIL-based immuno-oncology therapies.
Iovance Biotherapeutics reported its fourth quarter and full year 2021 results, highlighting continued advancements in TIL therapy for various solid tumors, notably melanoma and non-small cell lung cancer. The FDA granted fast track designation for lifileucel combined with pembrolizumab in metastatic melanoma. However, the company experienced a net loss of $99.3 million for Q4 2021 and $342.3 million for the full year, with rising R&D and administrative expenses. Iovance ended 2021 with a cash position of $602.1 million, projected to sustain operations into 2024.
Iovance Biotherapeutics announced the approval of stock options for 138,575 shares to nineteen new non-executive employees on February 17, 2022, under its 2021 Inducement Plan. The options, priced at $16.34 per share, will vest over three years, with one-third vesting on the first anniversary of each employee's start date. Iovance focuses on T cell-based cancer immunotherapy, aiming to deliver innovative treatments for solid tumors. The company’s lead candidate, lifileucel, shows potential to be the first approved one-time cell therapy for metastatic melanoma.
Iovance Biotherapeutics (NASDAQ: IOVA) will release its Q4 and full-year financial results on February 24, 2022, with a conference call at 4:30 p.m. ET. The company is focused on developing T cell-based cancer immunotherapies, particularly its lead product candidate, lifileucel, for metastatic melanoma, potentially becoming the first approved one-time cell therapy for solid tumors. The press release emphasizes ongoing innovation in cell therapy and highlights Iovance's commitment to improving cancer treatment.
Iovance Biotherapeutics announced the grant of 117,000 inducement stock options to 13 new non-executive employees as part of its 2021 Inducement Plan. The options were priced at $14.04, the closing stock price on January 21, 2022. Each option vests over three years, with one-third vesting on the first anniversary of the employee's start date and the remainder in quarterly installments. This action aligns with Nasdaq Listing Rule 5635(c)(4) and is part of Iovance's commitment to attract and retain talent in the field of cancer immunotherapy.
Iovance Biotherapeutics (NASDAQ: IOVA) announced the appointment of Dr. Raj K. Puri as Executive VP of Regulatory Strategy and Translational Medicine, effective Q1 2022. Dr. Puri brings over 33 years of FDA experience, notably leading the Division of Cellular and Gene Therapies. His expertise includes evaluating advanced therapies like T cell immunotherapy and cancer vaccines. Interim CEO Frederick G. Vogt expressed excitement about Dr. Puri's role in enhancing clinical and preclinical programs, contributing significantly to Iovance's mission of improving patient care through accessible T cell-based therapies.
Iovance Biotherapeutics announced successful manufacturing of tumor-infiltrating lymphocyte (TIL) therapy from cryopreserved tumor samples shipped from Australia. This innovation may address shipment challenges and enhance global access to TIL therapy. The company will present findings at the upcoming Tandem Meetings from February 2-6, 2022, in Salt Lake City, Utah. Two key abstracts will be presented, including results on ex vivo expansion of TILs and their treatment with decitabine. Iovance aims to lead in developing TIL therapies for cancer, particularly lifileucel for metastatic melanoma.
Iovance Biotherapeutics (NASDAQ: IOVA) announced that Fred Vogt, Interim CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. ET. The event will feature a live and archived webcast available on their website. Iovance is focused on developing T cell-based immunotherapies, with a lead candidate, lifileucel, showing promise for treating metastatic melanoma. The company emphasizes innovation in cell therapy aimed at improving cancer care.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) granted inducement stock options for 107,900 shares to eleven new non-executive employees on December 16, 2021. This grant is part of Iovance's 2021 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $17.80, equivalent to the closing price on the grant date. Each option vests over three years, with one-third vesting after one year and the rest quarterly thereafter, contingent on continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA) recently announced its participation in key December conferences focused on cancer immunotherapy. The company will engage in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 7 at 1:40 p.m. ET. Additionally, Iovance will present an on-demand poster at the ESMO Immuno-Oncology Annual Meeting from December 8-11, highlighting AKT inhibition's impact on TIL expansion. At the American Society of Hematology Annual Meeting from December 11-14, a poster will detail the Phase 1/2 study of IOV-2001 for chronic lymphocytic leukemia.
Iovance Biotherapeutics (NASDAQ: IOVA) announced the grant of inducement stock options for 168,575 shares to seven new non-executive employees on November 18, 2021. The options, part of the 2021 Inducement Plan, have an exercise price of $19.05, equal to the closing stock price on the grant date. Each option vests over three years, with one-third vesting on the first anniversary and the remainder in quarterly installments. This move is aligned with Iovance's focus on developing T cell-based cancer immunotherapies, notably its lead candidate lifileucel for metastatic melanoma.